[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346494-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346494-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fcigg-ge11-melittin-as-a-novel-egfr-targeted-peptibody-with-potent-cytotoxic-activity-against-cancer-cells","FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells","","Epidermal growth factor receptor (EGFR) overexpression across multiple cancer types makes EGFR a compelling therapeutic target. This study develops FcIgG-GE11-Melittin by fusing Melittin, a cytotoxic bee-venom peptide, to an EGFR-targeting peptibody (FcIgG-GE11). FcIgG-GE11 confers selective binding to EGFR-overexpressing cells, while Melittin triggers cell death via membrane-lytic activity. In vitro results show selective targeting and killing of EGFR-positive cancer cells with sparing of normal cells, supporting targeted therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fcigg-ge11-melittin-as-a-novel-egfr-targeted-peptibody-with-potent-cytotoxic-activity-against-cancer-cells/346494/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fcigg-ge11-melittin-as-a-novel-egfr-targeted-peptibody-with-potent-cytotoxic-activity-against-cancer-cells/346494.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is EGFR and why is it targeted in cancer therapy?","Question",{"text":63,"@type":64},"EGFR is a receptor tyrosine kinase whose activation promotes proliferation and survival. Overexpression of EGFR sustains these signaling pathways and contributes to oncogenesis, making it a promising therapy target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does FcIgG-GE11-Melittin work?",{"text":68,"@type":64},"FcIgG-GE11 enables specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity that disrupts cellular membranes.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges limit Melittin’s clinical use, and how does the study address them?",{"text":72,"@type":64},"Melittin faces nonspecific hemolysis, rapid clearance/degradation, and insufficient tumor accumulation. The study addresses these issues by incorporating Melittin into an EGFR-targeted peptibody format to improve specificity and reduce off-target effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346494,1790197391,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nFcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells  \nMalihe Hallaji1,5, Shima Fayaz1,5, Mojgan Allahyari2, Majid Golkar3, Kamran Pooshang-Bagheri4 & Pezhman Fard-Esfahani1􀀍  \nThe overexpression of epidermal growth factor receptor (EGFR) in various cancer types makes it an attractive target for therapeutic intervention. In this study, we designed a novel peptibody, FcIgG-GE11-Melittin, by fusing Melittin, a cytotoxic peptide from bee venom, to an EGFR-targeting peptibody (FcIgG-GE11). The FcIgG-GE11 component ensures specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity. We evaluated the efficacy of FcIgG-GE11-Melittin in vitro using EGFR-overexpressing cancer cell lines. Our results demonstrate that FcIgG-GE11-Melittin selectively targets and kills EGFR-positive cancer cells while sparing normal cells. These findings highlight the potential of FcIgG-GE11-Melittin as a targeted therapeutic agent for EGFR-overexpressing cancers.  \nKeywords Melittin, EGFR, Cancer, Targeted therapy, GE11, Peptibody  \nThe epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase that, upon activation by its ligands, triggers signaling pathways promoting cell proliferation and survival. Overexpression of EGFR, often due to gene amplification or increased transcription, leads to sustained activation of these pathways, contributing to oncogenesis1,2.  \nThe EGFR overexpression has been observed in various cancers, including lung, bladder, kidney, ovarian, head and neck, colorectal, breast and pancreatic cancers; making it a promising target for cancer therapy2. Recent advances in targeted therapies have focused on developing agents that specifically bind to EGFR and deliver cytotoxic payloads to cancer cells3. One such approach involves the use of peptibodies, which are fusion proteins consisting of a targeting peptide and an antibody Fc region4.  \nMelittin is the principal bioactive component of bee (Apis mellifera) venom. It comprises approximately 50–52% of the venom’s dry weight. Structurally, it is a cationic, amphiphilic peptide with a linear sequence of 26 amino acids and a molecular weight of 2840 Da5,6. Due to its positive charge, it is able to bind and interact with the negatively charged surfaces of cellular membranes. It disrupts cell membranes, leading to cell lysis and apoptosis7,8. At low concentrations, Melittin demonstrates potent anti-inflammatory activity; however, at higher doses, it is associated with adverse effects such as pruritus, inflammation, and localized pain9.  \nMelittin demonstrates significant anticancer activity through multiple mechanisms, including the induction of apoptosis, cell cycle arrest, modulation of oncogenic signaling pathways, inhibition of metastasis, and enhancement of chemo-and radiosensitivity10. Numerous studies have extensively investigated the regulatory role of Melittin in apoptosis, as well as its involvement in apoptotic mechanisms across various malignancies, including breast, ovarian, prostate, and lung cancers9.  \nRecent studies highlight the therapeutic potential of combining membrane-lytic peptides with targeting or chemotherapeutic entities. For example, the hybrid peptide NTP-385, generated by covalently linking LTX-315 to rhodamine B, showed up to 37-fold enhanced activity in adherent cancer cells and induced near-complete melanoma regression in mice by disrupting the nuclear membrane and triggering intrinsic apoptosis11. Similarly,  \n1Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran. 2Recombinant Protein Production Department, Research and Production Complex, Pasteur Institute of Iran, Karaj, Iran. 3Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran. 4Venom and Biotherapeutics Molecules Lab, Medical Biotechnology Department, Biotechno","cbCaibf7LibZ1a3v","https://ap.wps.com/l/cbCaibf7LibZ1a3v","pdf",1783237,"English","# Introduction\n## EGFR as a therapeutic target\n## Peptibodies and EGFR targeting\n## Melittin: structure and anticancer mechanisms\n## Limitations of linear anticancer peptides and stabilization strategies\n## Targeted delivery approaches\n## Rationale for FcIgG-GE11-Melittin","[{\"question\":\"What is EGFR and why is it targeted in cancer therapy?\",\"answer\":\"EGFR is a receptor tyrosine kinase whose activation promotes proliferation and survival. Overexpression of EGFR sustains these signaling pathways and contributes to oncogenesis, making it a promising therapy target.\"},{\"question\":\"How does FcIgG-GE11-Melittin work?\",\"answer\":\"FcIgG-GE11 enables specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity that disrupts cellular membranes.\"},{\"question\":\"What challenges limit Melittin’s clinical use, and how does the study address them?\",\"answer\":\"Melittin faces nonspecific hemolysis, rapid clearance/degradation, and insufficient tumor accumulation. The study addresses these issues by incorporating Melittin into an EGFR-targeted peptibody format to improve specificity and reduce off-target effects.\"}]","FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells | PDF",1790061694,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/134fb34efc8e51537158611cf2cce3e0.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/680ba4cb24e106eeb0ae0a330605d19f.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/263c711e91802ec3d017bb4acd464b24.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b402538dd114c67a683c853fcf4e06d4.webp",980,1287]